MUMBAI — Danish pharmaceutical major Novo Nordisk on Tuesday launched its Wegovy weight loss drug in India, debuting the medicine ahead of schedule and just months after American rival Eli Lilly began offering its own popular product in the country, which is grappling with rising obesity.
Wegovy, also known as semaglutide, is being launched in five different dosage sizes, ranging from 0.25 milligrams, priced at about 4,366 rupees ($50) per week, to 2.4 mg, which will cost around 6,503 rupees a week. That will make the drug much cheaper than in the U.S., where a dosage of 2.4 mg costs $337 per week.
